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The efficacy, safety and pharmacokinetics of adjunctive remacemide hydrochloride, a novel, low-affinity non-competitive
NMDA receptor channel blocker, were investigated in 28 adult patients with refractory epilepsy. This was a randomized double-
blind placebo-controlled cross-over study with five 4-week periods (baseline, treatment 1, washout, treatment 2, washout).
Baseline median seizure frequency was reduced by 33% following adjunctive remacemide hydrochloride 150 mg q.i.d. for
4 weeks compared with placebo (P = 0.041). Seizure frequency was reduced by ≥50% in 30% of patients treated with
remacemide hydrochloride compared with 9% on placebo. Mean plasma concentration of concomitant carbamazepine increased
by approximately 15% following adjunctive remacemide hydrochloride. There was no correlation between increased plasma
carbamazepine and reduced seizure frequency.
Remacemide hydrochloride was well tolerated and only three patients withdrew due to adverse events (two remacemide
hydrochloride, one placebo). Two patients died unexpectedly from their epilepsy during placebo treatment; both deaths were
considered by the investigators to be unrelated to earlier remacemide hydrochloride treatment.
This first specific efficacy investigation with adjunctive remacemide hydrochloride demonstrated anticonvulsant effects in
patients with refractory epilepsy. More extensive clinical investigation is justified.
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INTRODUCTION
Remacemide hydrochloride is currently in devel-
opment for the treatment of epilepsy. The par-
ent molecule and its active desglycinyl metabolite
are non-competitive, low-affinity N-methyl-D-aspartic
acid (NMDA) receptor channel blocking agents with
additional significant sodium fast channel activity1.
Non-competitive inhibition of NMDA receptors lo-
cated within neuronal membrane calcium channels is
thought to block the Ca2+ influx mediated by ma-
jor excitatory neurotransmitters, principally glutamate
and glycine. This results in reduced cortical neuronal
activity and potentially, suppression of seizures. This
mode of action appears to be different from other
AEDs. Remacemide hydrochloride may therefore rep-
resent the first of a new class of AED.
Previous studies in volunteers and patients with
epilepsy have shown remacemide hydrochloride ad-
ministered in doses up to 600 mg day−1 to be well tol-
erated2, 3. This was the first controlled study designed
to evaluate the efficacy of adjunctive remacemide hy-
drochloride in patients with refractory epilepsy.
MATERIALS AND METHODS
Trial design, patient inclusion and exclusion
criteria
This was a multicentre, placebo-controlled, ran-
domized, cross-over comparison of remacemide hy-
drochloride 600 mg day−1 and placebo as adjunctive
treatments in patients with refractory epilepsy. Fol-
lowing 28 days baseline evaluation, each patient was
sequentially randomized to both treatments, adminis-
tered as q.i.d. regimens for 28 days. Washout peri-
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ods of 28 days followed each treatment period. All
patients gave informed written consent to participate
in the study and continued to take stabilized doses of
either one or two pre-existing AEDs during the study
period. Overall, the study duration was 20 weeks with
patients seen every 2 weeks as outpatients.
Patients aged 18 to 65 taking optimal doses of
up to two antiepileptic drugs (not including benzodi-
azepines given p.r.n.), who experienced at least four
partial seizures per month in the 3 months prior to
the study period, were eligible for inclusion. Seizures
were defined in accordance with the International
Classification of Seizures4.
Patients excluded from entry included women of
child-bearing potential; patients with a clinically
significant medical condition other than epilepsy;
patients with a history of pseudoseizures or chronic
drug abuse; regular NSAID, antihistamine, sedative
and tranquillizer users; clinically obese patients; and
patients who had been involved in other experimental
procedures in the previous 3 months.
Test treatments, concomitant AEDs and
objectives
Identical remacemide hydrochloride 50 mg and
placebo capsules were used in the study. Patients ran-
domized to receive remacemide hydrochloride treat-
ment initially received 50 mg q.i.d. on day one, 100 mg
q.i.d. on day two and subsequently 150 mg q.i.d. for
days 3–26 inclusive. The final 2 days of remacemide
hydrochloride treatment involved a dose taper where
100 mg q.i.d. was administered on the penultimate day
and 50 mg q.i.d. on the final day. In the event of any
patient showing signs of intolerance to remacemide
hydrochloride 150 mg q.i.d., the protocol allowed for
dose reductions in 50 mg increments to 100 mg q.i.d.
or 50 mg q.i.d.
To counter any potential treatment order effects, the
order of treatment was randomized, resulting in two
patient groups. Group A received placebo in the first
double-blind period and remacemide hydrochloride in
the second. Treatment order was reversed for group B.
Primary objectives of the study were:
(1) To assess the efficacy of 28 days adjunc-
tive remacemide hydrochloride treatment
(600 mg day−1) in adult patients with poorly
controlled partial seizures with or without sec-
ondary generalization.
(2) To assess the safety and tolerability of adjunc-
tive remacemide hydrochloride (600 mg day−1)
during the study.
Table 1: Baseline demographics, seizure history and concomi-
tant AEDs.
Number of patients 28
Age (years) Mean 32.9
Range 17–57
Sex Male 26
Female 2
Seizure type Partial seizures only 24
Generalized seizures only 0
Partial and generalized seizures 4
Seizure frequency Mean 19.3
(No. per month) Median 9.0
Range 3–90
Duration of epilepsy Mean 23.3
(years) Range 5–41
Concomitant AEDsa Carbamazepine 24
(No. of patients) Sodium valproate 8
Phenytoin 4
Clobazam 5
Primidone 2
Vigabatrin 3
a Twelve patients were taking one concomitant AED, 14 patients
were taking two AEDs and two patients were receiving three
AEDs.
Secondary objectives were:
(1) To measure the plasma concentrations of
remacemide and the desglycinyl metabolite in
the presence of concomitant AED medications.
(2) To assess the effects of adjunctive remacemide
hydrochloride on seizure type during the study.
Patients remained on their pre-existing AED regimens
of one, or maximally, two drugs (excluding benzodi-
azepines taken p.r.n.), if dosages had been stable over
the 3 months prior to study entry. Plasma concentra-
tions of background AEDs were monitored during the
study. Details of concomitant AEDs are summarized
in Table 1.
Assessments
The primary efficacy variable in this trial was to-
tal seizure frequency, defined as the total count of
all seizure types during the 26-day treatment period
following dose escalation. Secondary efficacy assess-
ments undertaken included simple and complex partial
seizure counts, secondarily generalized seizure counts,
the number of seizure-free days and calculation of
percentage seizure reduction during treatment periods
compared with baseline.
Safety, tolerability and compliance with test medi-
cation were assessed at two-weekly outpatient visits,
where adverse events and withdrawals were recorded
and all patients received a detailed physical and neuro-
logical examination. Test medication was checked and
Remacemide hydrochloride treatment in patients with refractory epilepsy 539
Table 2: Median seizure frequency during the study.
Median for 26-day period
Baseline Remacemide Remacemide Placebo Placebo
hydrochloride hydrochloride treatment washout
treatment washout
Total seizures 9.0 6.0a 9.0 9.0 8.0
(n = 23)
Simple partial 0.0 0.0 0.0 2.5 0.5
(n = 10)
Complex partial 4.0 3.0 5.0 4.0 2.1
(n = 21)
Secondary generalized 4.5 1.0 2.7 6.0 2.5
(n = 18)
a Significant difference between remacemide hydrochloride and placebo (P < 0.05).
Table 3: Median seizure frequency during the first treatment
period.
Median for 26-day periods
Treatment Change from
Baseline period baseline
Remacemide (n = 11) 14.0 7.0 −3.0a
Placebo (n = 14) 6.5 7.5 1.5
a Significant reduction in seizure frequency (P < 0.05) when
compared to placebo (Mann-Whitney U -test).
counted. Blood and urine samples were taken at each
visit for laboratory testing (haematology, biochemistry
and urinalysis); blood samples for plasma remacemide
and desglycinyl metabolite assay were also taken half-
way through each double-blind study period. Patients
were followed up by telephone contact 3 months after
the study period to determine their health status.
Statistical analyses
Both parametric and non-parametric statistical meth-
ods were used in the analyses. Seizure frequency
data were analysed using Koch’s non-parametric two-
period cross-over model5 and also by direct com-
parison between the two treatment periods using the
Wilcoxon Matched Pairs Signed Ranks Test. Median
values for all seizure frequency data have been pre-
sented since the data were not normally distributed.
Analysis of variance was used to analyse vital signs
and laboratory data. All statistical tests were two-
tailed and significance was determined by reference to
the 5% level.
RESULTS
Patient demographics, seizure history and
concomitant medication
Twenty-eight Caucasian patients entered treatment, 25
completed the first double-blind period, 23 completed
both double-blind periods and 22 completed the study
(including both washout periods). The baseline demo-
graphic profile, seizure history and concomitant AED
details for entered patients are summarized in Table 1.
The two treatment order groups were well matched
with respect to demographic and seizure history vari-
ables.
Efficacy
Effects on total seizures
Analysis of the total seizures in the remacemide hy-
drochloride and placebo treatment periods, based on
data from 23 patients who completed both treatment
periods, showed a significant difference (P = 0.041)
between the two treatment periods. Patients experi-
enced fewer seizures during remacemide hydrochlo-
ride treatment (median seizure frequency 6.0) than
during placebo treatment (median seizure frequency
9.0). There were no significant period or carryover ef-
fects seen in these data (Table 2). Analyses of individ-
ual seizure types in the study (simple partial, complex
partial and secondary generalized seizures) showed no
statistically significant differences.
An additional analysis of seizure data from the
25 patients who completed the first treatment period
was also undertaken. This between-patient analysis
would not be affected by any period effect influences.
Patients treated with remacemide hydrochloride expe-
rienced a reduction in median seizure frequency of 3.0
seizures from baseline, compared with an increase of
1.5 with placebo (Table 3). This difference was statis-
tically significant (P = 0.029).
Percentage reduction in seizure frequency
For all patients, the percentage reduction in seizure
frequency from baseline for both treatments was cal-
culated. There was a trend in favour of remacemide
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hydrochloride treatment compared with placebo (P =
0.068). Median percentage reductions in total seizure
frequency for both adjunctive treatment periods are
summarized in Table 4.
The number and percentage of patients in both
treatment groups who experienced ≥50%, ≥75% and
100% reductions in total seizures are summarized in
Table 6. No patients were seizure free during placebo
treatment but 13% were seizure free on remacemide
hydrochloride.
Number of seizure-free days
More seizure-free days were recorded with
remacemide hydrochloride treatment (21.3 days) than
with placebo treatment (20.0 days) although the dif-
ference was not statistically significant.
Correlation between seizure frequency and
carbamazepine plasma concentration
During this study increased plasma carbamazepine
concentrations were observed during the remacemide
hydrochloride treatment period. There was no corre-
lation with reduction in seizure frequency, which sug-
gests that increased plasma carbamazepine concentra-
tions were unlikely to have contributed to the efficacy
effects recorded.
Safety
Data from all 28 patients randomized to test treat-
ment were included in the safety analyses: 27 patients
received remacemide hydrochloride and 26 received
placebo.
Adverse events
Twenty-eight patients reported adverse events during
the study: 19 during baseline, 25 during remacemide
hydrochloride treatment, 14 during remacemide hy-
drochloride washout, 16 during placebo treatment and
17 during placebo washout. Those adverse events re-
ported by more than one patient in the double-blind
treatment periods are detailed in Table 5.
The most common adverse event reported in the trial
was headache but this occurred with similar frequency
during remacemide hydrochloride and placebo treat-
ment. Adverse events which occurred more frequently
during remacemide hydrochloride treatment than dur-
ing placebo treatment included dyspepsia, dizziness,
abnormal gait, diplopia, abnormal vision, somnolence,
chest pain and fatigue.
No patient withdrew as a result of CNS adverse
events and no CNS adverse even were considered se-
rious by the investigators. Compliance with test treat-
ment was generally good. Five patients had their dose
of remacemide hydrochloride reduced as a conse-
quence of adverse events compared with two patients
on placebo treatment.
The chest pains experienced by three patients on
remacemide hydrochloride treatment and two patients
during placebo washout were investigated further.
ECG examination was unremarkable and the events
were not considered to be cardiac in origin or serious.
Seven of the 23 patients (30.4%) who completed
both double-blind treatment periods experienced an
increase in seizure frequency during remacemide hy-
drochloride treatment compared with baseline. In-
creased seizure frequency, however, was more preva-
lent in the other four phases of the study: 14 patients
(60.8%) had increased seizures during remacemide
hydrochloride washout; 12 patients (52%) during
placebo and nine (39%) during placebo washout, com-
pared with baseline. These observations suggest ad-
junctive remacemide hydrochloride treatment is un-
likely to have any significant pro-convulsive effects.
Serious adverse events and withdrawals
Two patients died during the study. One patient was
found dead in bed after 14 days of placebo treatment
and 46 days after completing remacemide hydrochlo-
ride treatment. Post-mortem examination revealed no
unusual findings and cause of death was given as
epilepsy. The second patient was found dead whilst
mowing his lawn after 28 days of placebo treatment
and 56 days after completing remacemide hydrochlo-
ride treatment. Post-mortem cause of death was given
as status epilepticus with the antecedent cause as an
old subdural abscess. Both deaths were considered to
be unrelated to remacemide hydrochloride treatment.
A further five patients experienced other serious ad-
verse events during the study. Two patients were hos-
pitalized for seizures whilst receiving placebo. One
patient receiving remacemide felt that a capsule of
study drug had lodged in his throat and was admit-
ted to hospital with chest pain and dysphagia. Another
patient was admitted to hospital due to a prolonged
seizure while taking remacemide. Both of these events
were considered by the investigator to be possibly re-
lated to study treatment. Another patient became un-
steady and drowsy and had double vision after 5 days
of treatment with remacemide hydrochloride. The in-
vestigator considered this event was probably related
to study treatment.
In addition to the two deaths, three patients dis-
continued the study due to adverse events. During
the remacemide hydrochloride treatment period, one
patient withdrew due to oesophageal pain and dyspha-
gia and another withdrew due to abdominal pain. Dur-
ing the placebo treatment period, one patient withdrew
due to abdominal pain and headache.
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Table 4: Summary of median percentage reductions in total seizure frequency.
Remacemide Remacemide Placebo Placebo
hydrochloride hydrochloride treatment washout
treatment washout
All patients (n = 23) 20.0 −11.1 −16.7 0.0
Negative percentages indicate an increase in seizure frequency.
Table 5: Numbers (and percentage) of patients reporting adverse events.
Preferred term Remacemide Placebo
hydrochloride (n = 27) (n = 26)
GI disorders Nausea 3 (11.1%) 3 (11.4%)
Vomiting 1 (3.7%) 2 (7.7%)
Dyspepsia 3 (11.1%) 0
Abdominal pain 2 (7.4%) 1 (3.8%)
CNS disorders Headache 8 (29.6%) 7 (26.9%)
Dizziness 5 (18.5%) 1 (3.8%)
Gait abnormality 3 (11.1%) 0
Vision disorders Diploplia 5 (18.5%) 1 (3.8%)
Vision abnormal 4 (14.8%) 1 (3.8%)
Psychiatric disorders Somnolence 6 (22.2%) 3 (11.4%)
Body as a whole Back pain 2 (7.4%) 0
Chest pain 3 (11.1%) 0
Chest pain substernal 2 (7.4%) 0
Death 0 2 (7.7%)
Fatigue 4 (14.8%) 1 (3.8%)
Table 6: Number (and percentage) of patients with a greater
than 50% reduction in seizure frequency.
Extent of seizure reduction Remacemide Placebo
hydrochloride n = 23
n = 23
≥50% Reduction 7 (30.4%) 2 (8.7%)
≥75% Reduction 6 (26.1%) 1 (4.3%)
100% Reduction 3 (13%) 0 (0%)
Laboratory data
There were no clinically significant changes in mean
values for haematological variables between the two
double-blind treatment periods. Six patients had re-
duced white cell counts during the study; these events
were attributed to concomitant carbamazepine use.
There were no further white cell decreases during
remacemide hydrochloride treatment.
Clinical chemistry was generally unremarkable. In-
dividual patient analyses revealed a number of out-
of-range values during the study for sodium, potas-
sium, urea, ALT, gamma GT, and ALP. Hepatic en-
zyme induction secondary to concomitant AED med-
ication is the most probable explanation for the ob-
served raised liver enzymes. There was no evidence
of further hepatic enzyme elevation in the presence
of remacemide hydrochloride or increased frequency
of abnormal laboratory assessments during treatment
with remacemide hydrochloride. Urinalysis was unre-
markable.
Vital signs, physical and neurological examinations
No significant differences were recorded between the
two treatment periods for vital signs, including sys-
tolic and diastolic blood pressure, heart rate, ECG ex-
amination, respiratory rate and temperature. Physical
examinations throughout the study showed no emer-
gence of any new physical abnormality arising as a
consequence of test treatments. Neurological assess-
ment revealed no new abnormal findings.
Pharmacokinetics
Remacemide and desglycinyl metabolite
Steady-state plasma concentrations of remacemide,
measured at mid-point during the double-blind treat-
ment periods, ranged from 22.9 to 233 µg l−1 at
13 hours post-dose and 3.2 hours post-dose, re-
spectively. The terminal half-life for remacemide is
approximately 3–4 hours, so variation in plasma
remacemide concentrations is largely explained by in-
dividual differences in the timing of blood samples
taken.
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Measurement of the desglycinyl metabolite was not
possible from all blood samples due to the assay
method’s limit of quantification (10 µg l−1). Where
the desglycinyl metabolite could be quantified, plasma
concentrations ranged from 12.8 µg l−1 (4 hours post-
dose) to 60.9 µg l−1 (2.1 hours post-dose). Less vari-
ation in metabolite concentrations, compared with the
parent drug, was expected due to the longer terminal
half-life and the flat steady-state profile of the desg-
lycinyl metabolite3.
Concomitant AEDs
Two patients were taking only sodium valproate, while
all other patients were receiving enzyme-inducing
AEDs. Carbamazepine was the most widely ad-
ministered concomitant AED during the study (24
patients). Analysis of carbamazepine concentrations,
determined during different phases of the study,
identified a significantly higher mean plasma car-
bamazepine concentration of 12.3 mg l−1 during
remacemide hydrochloride treatment compared with
10.7 mg l−1during placebo treatment. Plasma con-
centrations of carbamazepine were therefore increased
by approximately 15% in the presence of adjunctive
remacemide hydrochloride treatment.
DISCUSSION
This study demonstrated that adjunctive remacemide
hydrochloride, administered as 150 mg q.i.d. for
4 weeks, was effective to a statistically and clini-
cally significant extent in a small population of adult
patients with epilepsy refractory to long-term treat-
ment with conventional AEDs. Although treatment
duration was short and the study population small, the
response rate to remacemide hydrochloride was en-
couraging with median seizure frequency reduced by
approximately one third in the study population. Three
patients who completed both treatment periods were
seizure free on remacemide hydrochloride, whereas no
patient was seizure free during placebo treatment.
Adjunctive remacemide hydrochloride administered
at 600 mg day−1 was generally well tolerated. Al-
though all patients in the study reported adverse
events, most were transient and not serious. This
level of reported adverse events is not unusual in
a study of this duration involving patients with re-
fractory epilepsy taking long-standing concomitant
medications. The adverse events most commonly at-
tributed to remacemide hydrochloride treatment in-
volved the CNS and gastrointestinal tract. Gastroin-
testinal intolerance was responsible for the withdrawal
of two patients receiving remacemide hydrochloride,
although none of the CNS adverse events led to with-
drawal. Remacemide hydrochloride was not associ-
ated with any clinically significant changes in neu-
rological function, laboratory variables or vital signs
compared with placebo.
Plasma concentrations of carbamazepine were in-
creased in the presence of remacemide hydrochloride;
in this study the mean plasma carbamazepine concen-
tration increased by approximately 15%. There was
no correlation between increased carbamazepine con-
centrations and reduced seizure frequency in individ-
ual patients (r = 0.18, P = 0.43). The absence of
any correlation provides confidence that the modest
increase in plasma carbamazepine concentrations did
not contribute to the observed efficacy effects in the
study.
The two sudden epileptic deaths in this study oc-
curred during placebo treatment and in both cases the
investigators considered death to be unrelated to ear-
lier exposure to remacemide hydrochloride. The phe-
nomenon of sudden unexplained death in patients with
epilepsy is widely recognized and has been reported
by other investigators6, 7.
CONCLUSIONS
Remacemide hydrochloride has a novel mode of ac-
tion. Low-affinity NMDA receptor blocking activity
is believed to contribute to its anticonvulsant effect.
Adjunctive remacemide hydrochloride administered at
600 mg day−1 for approximately 1 month, to patients
with epilepsy refractory to pre-existing regimens of ei-
ther one or two conventional AEDs, was effective in
reducing seizures compared with placebo. Adjunctive
remacemide hydrochloride at 600 mg day−1 was gen-
erally well tolerated in most patients; CNS and gas-
trointestinal adverse events were most frequently re-
ported during remacemide hydrochloride treatment.
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